Press Releases April 29, 2026 08:47 AM

Century Aluminum Sets Date for First Quarter 2026 Earnings Announcement

Century Aluminum Company schedules Q1 2026 earnings release and conference call for May 7, 2026.

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
CENX

Century Aluminum Company announced it will release its first quarter 2026 earnings report on May 7, 2026, after the market closes, followed by a conference call to discuss the results. The event will be webcast live and available for replay on the company's website.

Century Aluminum Sets Date for First Quarter 2026 Earnings Announcement
CENX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Q1 2026 earnings announcement set for May 7, 2026, after market close.
  • Live webcast and conference call scheduled for 5:00 p.m. Eastern time the same day.
  • Earnings release and call offer investors insights into Century Aluminum's financial performance and operational updates.

CHICAGO, April 29, 2026 (GLOBE NEWSWIRE) -- Century Aluminum Company (NASDAQ: CENX) will report first quarter 2026 earnings on Thursday, May 7, 2026, after market close. The news release will be issued through GlobeNewswire.

The company will hold a follow-up conference call on Thursday, May 7, 2026, at 5:00 p.m. Eastern time.

The earnings call will be webcast live on the Century Aluminum Company website, located at www.centuryaluminum.com. Plan to begin the registration process at least 10 minutes before the live call is scheduled to begin. A replay of the webcast will be archived and available for replay approximately two hours following the live call.

Contact:
Investors: Chad Rigg, 312.696.3132, investorrelations@centuryaluminum.com
Media: Tawn Earnest, 614.698.6351, tawn.earnest@centuryaluminum.com


Risks

  • Market volatility may impact the stock price after earnings announcement.
  • Potential for earnings results to deviate from analyst expectations, influencing investor sentiment.
  • Aluminum industry factors such as commodity prices and supply chain disruptions could affect financial outcomes.

More from Press Releases

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026